Clinical trial
A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous…
NCT00373529 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00373529 |
|---|---|
| Title | A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II) |
| Official title | A Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients With Acute Myelogenous Leukemia (AML) for Whom Standard Induction Chemotherapy is Unlikely to be of Benefit |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myelogenous Leukemia, Acute Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | clofarabine |
| Enrollment | 116 |
| Start date | Oct 1, 2006 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2010 |
| First posted | Sep 8, 2006 |
| Last update posted | Apr 14, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: